<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Keratosis pilaris atrophicans</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Keratosis pilaris atrophicans</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Keratosis pilaris atrophicans</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Megan N Landis, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H298887915"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Keratosis pilaris atrophicans is a group of related disorders characterized by inflammatory keratotic papules that may result in alopecia and scarring. They include keratosis pilaris atrophicans faciei (also called ulerythema ophryogenes), atrophoderma vermiculatum, and keratosis follicularis spinulosa decalvans [<a href="#rid1">1</a>].</p><p>This topic will review the clinical presentation and management of keratosis pilaris atrophicans. Keratosis pilaris is discussed separately. (See  <a class="medical medical_review" href="/d/html/13663.html" rel="external">"Keratosis pilaris"</a>.)</p><p class="headingAnchor" id="H334573805"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Keratosis pilaris atrophicans is caused by abnormal keratinization of the follicular infundibulum, resulting in obstruction of the growing hair shaft and inflammation. Chronic inflammation leads to fibrosis, atrophy, shrinkage of the hair bulb, and alopecia. The association with several congenital syndromes due to partial monosomy or deletion in chromosome arm 18p suggests that the genes regulating the follicular keratinization may be located on chromosome 18p. (See <a class="local">'Associated syndromes'</a> below.)</p><p>Autosomal recessive keratosis pilaris atrophicans has been shown to be due to a mutation in the desmoglein 4 gene [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H61622824"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>The histopathologic features of keratosis pilaris atrophicans are nonspecific. In the early stages, there is an orthokeratotic keratin plug that blocks and dilates the orifice and upper portion of the follicular infundibulum (<a class="graphic graphic_picture graphicRef94925" href="/d/graphic/94925.html" rel="external">picture 1</a>) [<a href="#rid3">3</a>]. A twisted hair shaft may be trapped within this keratotic material, and a mild perivascular mononuclear cell infiltrate is usually present in the adjacent dermis. In later stages, dermal fibrosis and loss of hair follicles may be seen.</p><p class="headingAnchor" id="H298888379"><span class="h1">CLINICAL VARIANTS</span><span class="headingEndMark"> — </span>There are three clinical variants of keratosis pilaris atrophicans: ulerythema ophryogenes (also called keratosis pilaris atrophicans faciei), atrophoderma vermiculatum, and keratosis follicularis spinulosa decalvans (KFSD) [<a href="#rid4">4</a>]. Clinical features common to all forms include involvement of the face, in particular of the lateral eyebrows and cheeks; prominent erythema; and progression to an atrophic stage with loss of hairs in the involved areas [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H298887921"><span class="h2">Ulerythema ophryogenes</span><span class="headingEndMark"> — </span>Ulerythema ophryogenes (the prefix "ophryo-" refers to the eyebrow), also called "keratosis pilaris atrophicans faciei," primarily involves the eyebrow areas, resulting in atrophy and permanent loss of the involved hairs [<a href="#rid5">5,6</a>]. It usually occurs as a sporadic disease, but an autosomal dominant pattern of inheritance has been also reported [<a href="#rid1">1</a>]. </p><p>Ulerythema ophryogenes typically begins in the first months of life, with erythema and tiny keratotic follicular papules involving the lateral one-third of the eyebrows (<a class="graphic graphic_picture graphicRef90732" href="/d/graphic/90732.html" rel="external">picture 2B</a>). Over time, atrophy and loss of the eyebrows occur. The disorder may extend to the temples, cheeks, and forehead, resulting in a persistent facial erythema (<a class="graphic graphic_picture graphicRef95125" href="/d/graphic/95125.html" rel="external">picture 2A</a>). The affected areas may feel rough on gentle palpation. </p><p>The condition typically improves after puberty, but the loss of the lateral eyebrows and resultant scarring is often permanent. Simple keratosis pilaris is often present on the extensor aspects of the limbs. (See  <a class="medical medical_review" href="/d/html/13663.html" rel="external">"Keratosis pilaris"</a>.)</p><p class="headingAnchor" id="H61622897"><span class="h3">Associated syndromes</span><span class="headingEndMark"> — </span>Ulerythema ophryogenes is considered a marker of several congenital syndromes, such as Noonan syndrome, Rubinstein-Taybi syndrome, Cornelia de Lange syndrome, cardiofaciocutaneous syndrome, and chromosome 18p deletion [<a href="#rid7">7-12</a>]. (See  <a class="medical medical_review" href="/d/html/13558.html" rel="external">"Noonan syndrome"</a> and  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '16p13.3 deletion syndrome (Rubinstein-Taybi syndrome)'</a> and  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '18p deletion syndrome'</a>.) </p><p>An association has also been reported with woolly hair (MIM #194300), a group of autosomal dominant hair shaft disorders characterized by fine and tightly curly hair [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H298887927"><span class="h2">Atrophoderma vermiculatum</span><span class="headingEndMark"> — </span>Atrophoderma vermiculatum is a rare form of keratosis pilaris atrophicans, characterized by hyperkeratotic follicular papules with surrounding erythema on the cheeks, which evolve into coalescent follicular depressions in a honeycomb or worm-eaten pattern (<a class="graphic graphic_picture graphicRef90733" href="/d/graphic/90733.html" rel="external">picture 3</a>) [<a href="#rid14">14</a>]. It usually begins during childhood and progresses until puberty. The cheeks and preauricular regions are predominantly involved, with sparing of the eyebrows, eyelashes, and scalp.</p><p>Atrophoderma vermiculatum is a feature of Rombo syndrome, a genetic syndrome characterized by facial follicular atrophy, multiple milia, hypotrichosis, peripheral vasodilation with cyanosis, trichoepitheliomas, and predisposition to develop basal cell carcinomas [<a href="#rid15">15,16</a>]. Atrophoderma vermiculatum has also been associated with Loeys-Dietz syndrome, a rare autosomal aortic aneurysm syndrome with multiple skeletal abnormalities and dysmorphic facial features, caused by mutations in the transforming growth factor-beta receptor gene (<em>TGFBR</em>) [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H298887933"><span class="h2">Keratosis follicularis spinulosa decalvans</span><span class="headingEndMark"> — </span>Keratosis follicularis spinulosa decalvans (KFSD; MIM #308800) is an exceedingly rare variant of keratosis pilaris atrophicans characterized by follicular keratosis and progressive cicatricial alopecia involving the scalp, eyebrows, and eyelashes (<a class="graphic graphic_picture graphicRef87487 graphicRef87486" href="/d/graphic/87487.html" rel="external">picture 4A-B</a>) [<a href="#rid4">4</a>]. KFSD affects predominantly males, suggesting an X-linked mode of inheritance [<a href="#rid18">18</a>]. Mutations in the membrane-bound transcription factor protease site 2 (<em>MBTPS2</em>) gene on Xp22.12-p22.11 have been found in patients from several families with KFSD [<a href="#rid19">19-21</a>]. However, autosomal dominant forms have also been reported [<a href="#rid18">18,22</a>].</p><p>KFSD presents with facial erythema and extensive keratosis pilaris of the face, scalp, extremities, and trunk during early childhood (<a class="graphic graphic_picture graphicRef87486" href="/d/graphic/87486.html" rel="external">picture 4B</a>). Cicatricial alopecia of the scalp and eyebrows begins around puberty and slowly progresses with follicular inflammation and fibrosis.</p><p>Associated features include palmoplantar keratoderma, photophobia, blepharitis, and corneal dystrophy. Acne keloidalis nuchae and tufted hair folliculitis have been described in several patients with KFSD [<a href="#rid23">23-25</a>]. (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Cicatricial alopecia'</a>.)</p><p>KFSD shares many clinical features with ichthyosis follicularis, congenital atrichia, and photophobia (IFAP) syndrome (MIM #308205), an X-linked condition caused by mutations in the <em>MBTPS2</em> gene, in which affected neonates show widespread keratotic follicular papules with a sandpapery feel to the skin, atrichia or severe hypotrichosis, and photophobia [<a href="#rid4">4,26</a>].</p><p class="headingAnchor" id="H334574089"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of keratosis pilaris atrophicans is clinical. A skin biopsy is usually not necessary for the diagnosis. If performed, it shows nonspecific features including keratotic plugs in the pilosebaceous units and a mild perifollicular inflammatory infiltrate [<a href="#rid6">6</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p>The differential diagnosis of keratosis pilaris atrophicans includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Keratosis pilaris rubra faciei, a clinical variant of the common keratosis pilaris characterized by marked perifollicular erythema on the cheeks, forehead, and neck (<a class="graphic graphic_picture graphicRef77270" href="/d/graphic/77270.html" rel="external">picture 5</a>). (See  <a class="medical medical_review" href="/d/html/13663.html" rel="external">"Keratosis pilaris", section on 'Clinical variants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythromelanosis follicularis faciei et colli, another variant of keratosis pilaris presenting with erythema, hyperpigmentation, and follicular papules involving the cheeks, preauricular areas, and sides of the neck (<a class="graphic graphic_picture graphicRef90772" href="/d/graphic/90772.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/d/html/13663.html" rel="external">"Keratosis pilaris", section on 'Clinical variants'</a>.)</p><p></p><p class="headingAnchor" id="H298888862"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There are no effective therapies for keratosis pilaris atrophicans. The condition often improves with age. Ultraviolet (UV) protection is encouraged, since the condition is often photoexacerbated [<a href="#rid6">6</a>]. Topical corticosteroids, keratolytics, and topical retinoids are of limited benefit [<a href="#rid27">27</a>]. There are isolated reports of successful use of systemic retinoids for atrophoderma vermiculatum and keratosis follicularis spinulosa decalvans [<a href="#rid28">28,29</a>]. </p><p>Pulsed dye laser and intense pulsed light have been reported as effective in reducing erythema in small series of patients [<a href="#rid30">30,31</a>]. Hair transplant surgery has been reported for dormant keratosis pilaris atrophicans [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H298888953"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Keratosis pilaris atrophicans is a group of rare conditions characterized by follicular keratosis, chronic inflammation, and secondary scarring and alopecia. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Keratosis pilaris atrophicans comprises three distinct entities: ulerythema ophryogenes (<a class="graphic graphic_picture graphicRef95125 graphicRef90732" href="/d/graphic/95125.html" rel="external">picture 2A-B</a>) (also called keratosis pilaris atrophicans faciei), atrophoderma vermiculatum (<a class="graphic graphic_picture graphicRef90733" href="/d/graphic/90733.html" rel="external">picture 3</a>), and keratosis follicularis spinulosa decalvans (<a class="graphic graphic_picture graphicRef87487 graphicRef87486" href="/d/graphic/87487.html" rel="external">picture 4A-B</a>). Clinical features common to all forms include involvement of the face, in particular of the lateral eyebrows and cheeks; prominent erythema; and progression to an atrophic stage with loss of hairs in the involved areas. (See <a class="local">'Clinical variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – There is no effective treatment for keratosis pilaris atrophicans. It often improves with age, but the loss of eyebrows and scarring are typically permanent. Topical therapies, including corticosteroids, keratolytics, and retinoids, are of limited benefit. Pulsed dye laser and intense pulsed light have been reported as effective in reducing erythema. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H384295254"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jennifer Perryman, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Callaway SR, Lesher JL Jr. Keratosis pilaris atrophicans: case series and review. Pediatr Dermatol 2004; 21:14.</a></li><li><a class="nounderline abstract_t">Cohen-Barak E, Danial-Farran N, Hammad H, et al. Desmoglein 4 Mutation Underlies Autosomal Recessive Keratosis Pilaris Atrophicans. Acta Derm Venereol 2018; 98:809.</a></li><li class="breakAll">Ioffreda MD. Inflammatory diseases of the hair follicles, sweat glands, and cartilage. In: Lever's Histopathology of the Skin, 9th ed, Elder D, Elenitsas R, Johnson BL, et al (Eds), Lippincott Williams and Wilkins, 2005. p.469.</li><li class="breakAll">Paller AS, Mancini AJ. Disorders of hair and nails. In: Hurwitz Clinical Pediatric Dermatology, 4th ed, Elsevier Saunders, 2011.</li><li><a class="nounderline abstract_t">Arnold AW, Buechner SA. [Keratosis pilaris and keratosis pilaris atrophicans faciei]. J Dtsch Dermatol Ges 2006; 4:319.</a></li><li><a class="nounderline abstract_t">Morton CM, Bhate C, Janniger CK, Schwartz RA. Ulerythema ophryogenes: updates and insights. Cutis 2014; 93:83.</a></li><li><a class="nounderline abstract_t">Zouboulis CC, Stratakis CA, Gollnick HP, Orfanos CE. Keratosis pilaris/ulerythema ophryogenes and 18p deletion: is it possible that the LAMA1 gene is involved? J Med Genet 2001; 38:127.</a></li><li><a class="nounderline abstract_t">Siegel DH, McKenzie J, Frieden IJ, Rauen KA. Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. Br J Dermatol 2011; 164:521.</a></li><li><a class="nounderline abstract_t">Guidry JA, Rees A, Chan AJ, et al. Ulerythema ophryogenes and Noonan syndrome. Dermatol Online J 2013; 19:14.</a></li><li><a class="nounderline abstract_t">Flórez A, Fernández-Redondo V, Toribio J. Ulerythema ophryogenes in Cornelia de Lange syndrome. Pediatr Dermatol 2002; 19:42.</a></li><li><a class="nounderline abstract_t">Gómez Centeno P, Rosón E, Peteiro C, et al. Rubinstein--Taybi syndrome and ulerythema ophryogenes in a 9-year-old boy. Pediatr Dermatol 1999; 16:134.</a></li><li><a class="nounderline abstract_t">Carvalho CA, Carvalho AV, Kiss A, et al. Keratosis pilaris and ulerythema ophryogenes in a woman with monosomy of the short arm of chromosome 18. An Bras Dermatol 2011; 86:S42.</a></li><li><a class="nounderline abstract_t">Chien AJ, Valentine MC, Sybert VP. Hereditary woolly hair and keratosis pilaris. J Am Acad Dermatol 2006; 54:S35.</a></li><li><a class="nounderline abstract_t">Luria RB, Conologue T. Atrophoderma vermiculatum: a case report and review of the literature on keratosis pilaris atrophicans. Cutis 2009; 83:83.</a></li><li><a class="nounderline abstract_t">Michaëlsson G, Olsson E, Westermark P. The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis. Acta Derm Venereol 1981; 61:497.</a></li><li><a class="nounderline abstract_t">Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol 2011; 165:30.</a></li><li><a class="nounderline abstract_t">van Dijk FS, Brittain H, Boerma R, et al. Atrophoderma Vermiculatum: A Cutaneous Feature of Loeys-Dietz Syndrome. JAMA Dermatol 2015; 151:675.</a></li><li><a class="nounderline abstract_t">Castori M, Covaciu C, Paradisi M, Zambruno G. Clinical and genetic heterogeneity in keratosis follicularis spinulosa decalvans. Eur J Med Genet 2009; 52:53.</a></li><li><a class="nounderline abstract_t">Bornholdt D, Atkinson TP, Bouadjar B, et al. Genotype-phenotype correlations emerging from the identification of missense mutations in MBTPS2. Hum Mutat 2013; 34:587.</a></li><li><a class="nounderline abstract_t">Fong K, Wedgeworth EK, Lai-Cheong JE, et al. MBTPS2 mutation in a British pedigree with keratosis follicularis spinulosa decalvans. Clin Exp Dermatol 2012; 37:631.</a></li><li><a class="nounderline abstract_t">Aten E, Brasz LC, Bornholdt D, et al. Keratosis Follicularis Spinulosa Decalvans is caused by mutations in MBTPS2. Hum Mutat 2010; 31:1125.</a></li><li><a class="nounderline abstract_t">Bellet JS, Kaplan AL, Selim MA, Olsen EA. Keratosis follicularis spinulosa decalvans in a family. J Am Acad Dermatol 2008; 58:499.</a></li><li><a class="nounderline abstract_t">Janjua SA, Iftikhar N, Pastar Z, Hosler GA. Keratosis follicularis spinulosa decalvans associated with acne keloidalis nuchae and tufted hair folliculitis. Am J Clin Dermatol 2008; 9:137.</a></li><li><a class="nounderline abstract_t">Goh MS, Magee J, Chong AH. Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae. Australas J Dermatol 2005; 46:257.</a></li><li><a class="nounderline abstract_t">Richard G, Harth W. [Keratosis follicularis spinulosa decalvans. Therapy with isotretinoin and etretinate in the inflammatory stage]. Hautarzt 1993; 44:529.</a></li><li><a class="nounderline abstract_t">Oeffner F, Martinez F, Schaffer J, et al. Intronic mutations affecting splicing of MBTPS2 cause ichthyosis follicularis, alopecia and photophobia (IFAP) syndrome. Exp Dermatol 2011; 20:447.</a></li><li><a class="nounderline abstract_t">Baden HP, Byers HR. Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans. Arch Dermatol 1994; 130:469.</a></li><li><a class="nounderline abstract_t">Weightman W. A case of atrophoderma vermiculatum responding to isotretinoin. Clin Exp Dermatol 1998; 23:89.</a></li><li><a class="nounderline abstract_t">Apalla Z, Karakatsanis G, Papageorgiou M, et al. A case of atrophoderma vermiculatum responding to systemic isotretinoin. J Dermatol Case Rep 2009; 3:62.</a></li><li><a class="nounderline abstract_t">Alcántara González J, Boixeda P, Truchuelo Díez MT, Fleta Asín B. Keratosis pilaris rubra and keratosis pilaris atrophicans faciei treated with pulsed dye laser: report of 10 cases. J Eur Acad Dermatol Venereol 2011; 25:710.</a></li><li><a class="nounderline abstract_t">Rodríguez-Lojo R, Pozo JD, Barja JM, et al. Keratosis pilaris atrophicans: treatment with intense pulsed light in four patients. J Cosmet Laser Ther 2010; 12:188.</a></li><li><a class="nounderline abstract_t">Miranda BH, Farjo N, Farjo B. Eyebrow reconstruction in dormant keratosis pilaris atrophicans. J Plast Reconstr Aesthet Surg 2011; 64:e303.</a></li></ol></div><div id="topicVersionRevision">Topic 91429 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871319" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Keratosis pilaris atrophicans: case series and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29796690" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Desmoglein 4 Mutation Underlies Autosomal Recessive Keratosis Pilaris Atrophicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29796690" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Desmoglein 4 Mutation Underlies Autosomal Recessive Keratosis Pilaris Atrophicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29796690" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Desmoglein 4 Mutation Underlies Autosomal Recessive Keratosis Pilaris Atrophicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638061" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : [Keratosis pilaris and keratosis pilaris atrophicans faciei].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24605344" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ulerythema ophryogenes: updates and insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11288714" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Keratosis pilaris/ulerythema ophryogenes and 18p deletion: is it possible that the LAMA1 gene is involved?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21062266" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23473284" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ulerythema ophryogenes and Noonan syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11860570" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ulerythema ophryogenes in Cornelia de Lange syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10337678" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rubinstein--Taybi syndrome and ulerythema ophryogenes in a 9-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068768" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Keratosis pilaris and ulerythema ophryogenes in a woman with monosomy of the short arm of chromosome 18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427989" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hereditary woolly hair and keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19326693" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Atrophoderma vermiculatum: a case report and review of the literature on keratosis pilaris atrophicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6177160" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Rombo syndrome: a familial disorder with vermiculate atrophoderma, milia, hypotrichosis, trichoepitheliomas, basal cell carcinomas and peripheral vasodilation with cyanosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21428980" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hereditary tumour syndromes featuring basal cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25564957" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Atrophoderma Vermiculatum: A Cutaneous Feature of Loeys-Dietz Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984066" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical and genetic heterogeneity in keratosis follicularis spinulosa decalvans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23316014" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genotype-phenotype correlations emerging from the identification of missense mutations in MBTPS2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22816986" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : MBTPS2 mutation in a British pedigree with keratosis follicularis spinulosa decalvans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20672378" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Keratosis Follicularis Spinulosa Decalvans is caused by mutations in MBTPS2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280351" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Keratosis follicularis spinulosa decalvans in a family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284270" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Keratosis follicularis spinulosa decalvans associated with acne keloidalis nuchae and tufted hair folliculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197427" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Keratosis follicularis spinulosa decalvans and acne keloidalis nuchae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8376108" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Keratosis follicularis spinulosa decalvans. Therapy with isotretinoin and etretinate in the inflammatory stage].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21426410" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intronic mutations affecting splicing of MBTPS2 cause ichthyosis follicularis, alopecia and photophobia (IFAP) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8166484" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692315" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A case of atrophoderma vermiculatum responding to isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21886736" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A case of atrophoderma vermiculatum responding to systemic isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20569297" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Keratosis pilaris rubra and keratosis pilaris atrophicans faciei treated with pulsed dye laser: report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20590370" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Keratosis pilaris atrophicans: treatment with intense pulsed light in four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21723799" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Eyebrow reconstruction in dormant keratosis pilaris atrophicans.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
